Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX101 gene therapy study in RPE65-associated inherited retinal degeneration
CTR20221608Phase 3Active
- Sponsor
- Lumsun Biotech
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 765IGF-MTX in RPE65-associated inherited retinal degeneration (RPE65-IRD), sponsored by Lumsun Biotech. Started Jul 2022; status: active.
02
Drugs
765IGF-MTX
03
Conditions
RPE65-associated inherited retinal degeneration (RPE65-IRD)
Beyond the preview
Go deeper on CTR20221608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221608.